Skip to content

A randomized controlled clinical trial of compound colloidal sulfur emulsion in improving the efficacy and safety of acne vulgaris

A randomized controlled clinical trial of compound colloidal sulfur emulsion in improving the efficacy and safety of acne vulgaris

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062679
Enrollment
Unknown
Registered
2022-08-15
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris

Interventions

Test Group:Compound colloidal sulfur emulsion for external use
Control Group:Benzoyl Peroxide Gel for external use

Sponsors

Shenzhen Luohu District Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. The subject must have a full understanding of the content, process and possible adverse reactions before the trial, and have voluntarily signed a written informed consent; 2. Subjects were able to communicate well with investigators and to complete the trial in accordance with protocol; 3. Aged >= 14 years (including boundary values, subjects under 18 years old required both guardian and informed consent); 4. Gender: male and female; 5. Patients with moderate (Grade II) acne Pillsbury 4-grade skin lesions, which mainly presented on the face; 6. Patients voluntarily participated in the clinical observation and signed an informed consent acne vulgaris. Willing to cooperate with follow-up observation. Good communication and understanding skills.

Exclusion criteria

Exclusion criteria: 1. Pillsbury's 4-step classification for mild (grade I) , moderate (Grade III) and severe (Grade IV) acne vulgaris; 2. Systemic treatment within 3 months (tretinoin and photodynamic therapy within 6 months); 3. The patients were treated with topical acne drugs or efficacy skin care products one week before they were enrolled in the study group; 4. The patients were complicated with other skin diseases which might affect the efficacy evaluation; 5. Related diseases of female patients treated with estrogen or estrogen-like hormone; 6. Patients with allergic history to the drugs and ingredients; 7. Patients with severe heart, brain, lung, liver and kidney function impairment; 8. Pregnant and lactating women; 9. Patients with a history of mental illness, recent history of alcohol abuse or drug abuse; 10. Patients who are unwilling to sign the informed consent form, and those who are unwilling to cooperate.

Design outcomes

Primary

MeasureTime frame
Number of skin lesions;Global Acne Grading System quantitative indicators;

Countries

China

Contacts

Public ContactZhao Qing

Shenzhen Luohu District Hospital of Traditional Chinese Medicine

kaixinzq@126.com+86 13632928217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026